This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc. In Connection With The Sale Of The Company To Mallinckrodt Plc

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc (“MNK”).

Click here to learn more about the investigation http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html, or call: 877-534-2590. There is no cost or obligation to you.

Cadence announced that the transaction is a Tender Offer, which should close, unless extended, 20 days after commencement. Under the terms of the transaction, Cadence shareholders will receive only $14.00 in cash for each share of Cadence stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cadence for not acting in the Company’s shareholders' best interests in connection with the sale process.

The transaction may undervalue the Company as it is below the premium paid in comparable transactions and an analyst has set a $15.00 per share price target on Cadence stock. In addition, the Company has announced OFIRMEV has continued to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013.

If you own shares of Cadence common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, or by visiting http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs